For most kids, managing a busy schedule of sports and school is just part of growing up. For Greg Stanoch of Chadds Ford, it also meant multiple insulin injections every single day.
“It’s really hard for me to say this, but I couldn’t really be a kid,” the 15-year-old said. “It was a lot of anxiety, a lot of stress.”
Now, that may be about to change, not just for Greg, but for children with diabetes across the country, reports Stephanie Stahl for CBS News Philadelphia.
Stanoch was one of the participants in a four-year clinical trial for Afrezza, an inhaled insulin that the U.S. Food and Drug Administration has just approved for pediatric use.
Diagnosed with Type 1 Diabetes in first grade, Greg had spent years relying on daily injections to manage his blood sugar.
His father, David Stanoch, was initially hesitant to enroll his son in a clinical trial, but the family took comfort knowing Afrezza had already been approved for adults for more than a decade.
For an active teenager who loves sports, including frisbee, the switch to inhaled insulin has been transformative.
Doctors involved in the study confirmed the inhaled insulin performed on par with traditional injections, delivering the same results without the needles.
Greg called the FDA approval “amazing” and said he’s thrilled that other kids will now have access to what changed his life.
Don’t miss the full report at CBS News Philadelphia, including more on Greg’s story and what this FDA approval could mean for the millions of children living with diabetes across the country.
_______
